SavedAdd your journal

Journals / The Anatolian Journal of Cardiology / 2017 / Cilt: 18 - Sayı: 6

Relationship of activin A levels with clinical presentation, extent, and severity of coronary artery disease

Nadia BOUZİDİ
Fethi BETBOUT
Faouzi MAATOUK
Habib GAMRA
Pages
402–409
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In multiple analysis of the overall population, male gender (?=-0.260; 95% CI: -617.39 to -110.04; p=0.005) was an independent predictor of activin A levels.Conclusion: This study indicated that activin A can not be a predictive marker in CAD and is not associated with extensive and severe CAD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to evaluate the relationship of serum activin A levels with risk factors, clinical presentation, biochemical marker levels, extent, and severity of atherosclerotic coronary artery disease (CAD).Methods: In total, 310 CAD patients [92 with ST-segment elevation myocardial infarction (STEMI), 111 with non-STEMI (NSTEMI), and 107 with unstable angina (UA)] and 207 healthy subjects (controls) were enrolled.
📊
Key Findings & Data:Angiographic measurements were performed in patients and not in the healthy subjects.Results: Activin A levels were higher in all patient groups than in controls (patients vs. controls, p=0.041; NSTEMI vs.
💡
Conclusion & Impact:In multiple analysis of the overall population, male gender (?=-0.260; 95% CI: -617.39 to -110.04; p=0.005) was an independent predictor of activin A levels.Conclusion: This study indicated that activin A can not be a predictive marker in CAD and is not associated with extensive and severe CAD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to evaluate the relationship of serum activin A levels with risk factors, clinical presentation, biochemical marker levels, extent, and severity of atherosclerotic coronary artery disease (CAD).Methods: In total, 310 CAD patients [92 with ST-segment elevation myocardial infarction (STEMI), 111 with non-STEMI (NSTEMI), and 107 with unstable angina (UA)] and 207 healthy subjects (controls) were enrolled. Activin A levels in all participants were measured using ELISA. Angiographic measurements were performed in patients and not in the healthy subjects.Results: Activin A levels were higher in all patient groups than in controls (patients vs. controls, p=0.041; NSTEMI vs. UA, p=0.744; STEMI vs. UA, p=0.172; NSTEMI vs. STEMI, p=0.104). According to the cut-off value of activin A level, patients with high and low activin A levels had a similar distribution of clinical and biochemical variables but the prevalence of severe stenosis was observed in groups with high activin A levels. Our results revealed that activin A levels did not decrease as thrombolysis in myocardial infarction (risk score increased (p=0.590). The area under the ROC curve for activin A levels in patients was 0.590±0.047 (95% CI: 0.439-0.591, p=0.193). In multiple analysis of the overall population, male gender (?=-0.260; 95% CI: -617.39 to -110.04; p=0.005) was an independent predictor of activin A levels.Conclusion: This study indicated that activin A can not be a predictive marker in CAD and is not associated with extensive and severe CAD. In contrast, the increase in activin A levels in patients, especially in patients with different clinical groups of acute coronary syndromes, suggested its involvement in atherosclerosis.

🔖

Cite This Article

BOUZİDİ, N., BETBOUT, F., MAATOUK, F., GAMRA, H. (2017). Relationship of activin A levels with clinical presentation, extent, and severity of coronary artery disease. The Anatolian Journal of Cardiology, Cilt: 18 - Sayı: 6, 402–409. https://ajindex.com/articles/365375

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Park CS, Hong OK, Kim MK, Chung WB, Choi YS, Baek KH, et al. Serum Bone Morphogenic Protein-4 contributes to discriminating coronary artery disease severity. Medicine 2015; 94: e1530
  2. Krecki R, Drozdz J, Szczesniak P, Orszulak-Michalak D, KrzeminskaPakula M. Novel atherogenesis markers for identification of patients with a multivessel coronary artery disease. Kardiol Pol 2008; 66: 1173-80
  3. Rothenbacher D, Müller-Scholze S, Herder C, Koenig W, Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194-9
  4. Caselli C, De Graaf MA, Lorenzoni V, Rovai D, Marinelli M, Del Ry S, et al. HDL cholesterol, leptin interleukine-6 predtict higher risk coronary anatomy assessed by CT angiography in patients with stable chest pain. Atherosclerosis 2015; 241: 55-61
  5. Hayashi Y, Maeshima K, Goto F, Kojima I. Activin A as a critical mediator of capillary formation: Interaction with the fibroblast growth factor action. Endocr J 2007; 54: 311-8
  6. Smith C, Yndestad A, Halvorsen B, Ueland T, Waehre T, Otterdal K, et al. Potential anti-inflammatory role of activin A in acute coronary syndromes. J Am Coll Cardiol 2004; 44: 369-75
  7. Engelse MA, Neele JM, van Achterberg TA, van Aken BE, van Schaik RH, Pannekoek H, et al. Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells. Circ Res 1999; 85: 931-9
  8. Mogensen UM, Jensen T, Køber L, Kelbæk H, Mathiesen AS, Dixen U, et al. Cardiovascular autonomic neuropathy and subclinical car- diovascular disease in normoalbuminuric Type 1 diabetic patients. Diabetes 2012; 61: 1822-30
  9. Groenendijk BC, Benus GF, Klous A, Pacheco YM, Volger OL, Fledderus JO, et al. Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF- ?. Exp Cell Res 2011; 317: 131-42
  10. Miyoshi T, Hirohata S, Uesugi T, Hirota M, Ohnishi H, Nogami K, et al. Relationship between activin A level and infarct size in patients with acute myocardial infarction undergoing successful primary coronary intervention. Clin Chim Acta 2009; 401: 3-7
  11. Lin JF, Hsu SY, Teng MS, Wu S, Hsieh CA, Jang SJ, et al. Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction. Acta Cardiol Sin 2016; 32: 420-7
  12. Yndestad A, Ueland T, Øie E, Florholmen G, Halvorsen B, Attramadal H, et al. Elevated le